ARIZONA HEALTH CARE COST

CONTAINMENT SYSTEM

AHCCCS CONTRACTOR OPERATIONS MANUAL

CHAPTER 300 - FINANCE

302 – COST SETTLEMENT FOR CORONAVIRUS DISEASE OF 2019 VACCINE

EFFECTIVE DATES: 10/01/21, 03/01/22, 10/01/22, 10/01/23, 06/12/25

APPROVAL DATES: 08/03/21, 01/24/22, 05/12/22, 08/01/23, 12/21/23, 04/09/25

I. PURPOSE

This Policy applies to ACC, ACC-RBHA, ALTCS E/PD, DCS CHP (CHP), and DES DDD (DDD) Contractors. This Policy establishes requirements for cost settlement for Coronavirus Disease of 2019 (COVID-19) vaccine costs and Vaccine Administration Costs for October 1, 2021, to September 30, 2024 (Contract Year Ending [CYE] 22, CYE 23, and CYE 24 only). The Contractor is not contractually at risk for the cost of the vaccine or the Vaccine Administration Costs during CYE 22, CYE 23, and CYE 24. The anticipated costs have not been included in the CYE 22, CYE 23, or CYE 24 capitation rates; therefore, the Contractor will be provided payment via cost settlement as delineated in this Policy.

II. DEFINITIONS

For purposes of this Policy, the following terms are defined as:

CONTRACT YEAR For AHCCCS Contractors and Fee-For-Service (FFS) Programs,

the contract year runs from October 1 through September 30.

CONTRACTOR An organization or entity that has a prepaid capitated Contract

with AHCCCS pursuant to ARS 36-2904, ARS 36-2940, ARS 36-2944, or Chapter 34 of ARS Title 36, to provide goods and services to members either directly or through subcontracts with providers, in conformance with contractual requirements and Federal and State law, rule, regulations, and policies.

MEMBER An eligible individual who is enrolled in AHCCCS, as specified in

ARS 36-2931, 36-2901, 36-2901.01 and ARS 36-2981. Also referred to as Title XIX/XXI member or Medicaid member. When applicable, MEMBER may also or alternatively refer to an enrolled individual's Health Care Decision Maker (HCDM) or

Designated Representative (DR).

PREMIUM TAX The tax imposed pursuant to ARS 36-2905 and ARS 36-

2944.01 for all payments made to the Contractor for the

Contract year.

VACCINE ADMINISTRATION

COST

The cost of administering the vaccine. This is the cost of administering the COVID-19 vaccine using the CMS 1500 medical form, in the 837P format or through the point-of-sale

(POS) system.

ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM

AHCCCS CONTRACTOR OPERATIONS MANUAL

CHAPTER 300 - FINANCE

VACCINE COST

The cost of the vaccine. This is the cost of the COVID-19 vaccine using the CMS 1500 medical form, in the 837P format or through the point-of-sale (POS) system. Prior to September 11, 2023, the COVID-19 vaccines were provided at no charge from the Federal government. After September 11, 2023, the vaccine cost will also be cost settled at the lesser of the Medicare Average Sales Price (ASP) file rate or the amount paid by the Contractor to the provider.

III. POLICY

A. GENERAL

This cost settlement shall relate solely to COVID-19 vaccine cost and Vaccine Administration Costs made by the Contractor for Title XIX and Title XXI members using the following list of approved Current Procedural Terminology (CPT) and National Drug Codes (NDC) codes. State only members shall not be included in this reconciliation.

The following CPT will be used for all vaccines not provided in a pharmacy. If the code has an asterisk (*) next to it, it is not currently approved for use or not covered.

| CPT CODE | DESCRIPTION | EFFECTIVE DATES |
|----------|---|--------------------|
| 91318 | Pfizer-BioNTech COVID-19 Vaccine 2023-2024 Formula | 9/11/23-TBD |
| 91319 | Pfizer-BioNTech COVID-19 Vaccine 2023-2024 Formula | 9/11/23-TBD |
| 91320 | COMIRNATY (COVID-19 Vaccine, mRNA) 2023-2024 Formula | 9/11/23-TBD |
| 91321 | Moderna COVID-19 Vaccine 2023-2024 Formula | 9/11/23-TBD |
| 91322 | SPIKEVAX 2023-2024 Formula | 9/11/23-TBD |
| 91304 | Novavax COVID-19 Vaccine | 7/13/22-TBD |
| 90480 | Immunization Administration by Intramuscular Injection | 9/11/23-TBD |
| 0001A | D1A Pfizer-BioNTech COVID-19 Vaccine Administration First Dose | |
| 0002A | 0002A Pfizer-BioNTech COVID-19 Vaccine Administration Second Dose | |
| 0003A | 0003A Pfizer-BioNTech COVID-19 Vaccine Administration Third Dose | |
| 0004A | 0004A Pfizer-BioNTech COVID-19 Vaccine Booster | |
| 91300 | Pfizer-BioNTech COVID-19 Vaccine | |
| 0011A | 0011A Moderna COVID-19 Vaccine Administration First Dose | |



CHAPTER 300 – FINANCE

| CPT CODE | DE DESCRIPTION | |
|---|---|----------------------|
| 0012A | Moderna COVID-19 Vaccine Administration Second Dose | |
| 0013A | Moderna COVID-19 Vaccine Administration Third Dose | 8/12/21- 4/17/23 |
| 91301 | Moderna COVID-19 Vaccine | 12/18/20- 4/17/23 |
| 0031A | Janssen COVID-19 Vaccine Administration Single Dose | 2/27/21- 5/31/23 |
| 0034A | Janssen COVID-19 Vaccine Booster | 10/20/21- 5/31/23 |
| 91303 | Janssen COVID-19 Vaccine | 2/27/21- 5/31/23 |
| 0021A* | Astra Zeneca COVID-19 Vaccine Administration First Dose | TBD |
| 0022A* | Astra Zeneca COVID-19 Vaccine Administration Second Dose | TBD |
| 91302* | Astra Zeneca COVID-19 Vaccine | TBD |
| 0041A | Novavax COVID-19 Vaccine Administration First Dose | 7/13/22- 10/31/23 |
| 0042A | Novavax COVID-19 Vaccine Administration First Dose | |
| 0044A | Novavax COVID-19 Vaccine Adjuvanted Administration Booster | |
| 0051A | 0051A Pfizer-BioNTech COVID-19 Vaccine Administration First Dose | |
| 0052A | D052A Pfizer-BioNTech COVID-19 Vaccine Administration Second Dose | |
| 0053A | A Pfizer-BioNTech COVID-19 Vaccine Administration Third Dose | |
| 0054A | A Pfizer-BioNTech COVID-19 Vaccine Administration Booster | |
| 91305 | Pfizer-BioNTech COVID-19 Vaccine | 1/3/22- 4/17/23 |
| 0064A | 4A Moderna COVID-19 Vaccine Low Dose - Booster | |
| 91306 Moderna COVID-19 Vaccine Low Dose | | 10/1/21- 4/17/23 |



CHAPTER 300 – FINANCE

| CPT CODE | DESCRIPTION | EFFECTIVE DATES |
|---|---|----------------------|
| 0071A | Pfizer-BioNTech COVID-19 Vaccine Tris-Sucrose— First dose Administration | 10/29/21- 4/17/23 |
| 0072A | Pfizer-BioNTech COVID-19 Vaccine Tris-Sucrose-Second dose Administration | 10/29/21- 4/17/23 |
| 0073A | Pfizer-BioNTech COVID-19 Vaccine Tris-Sucrose-Third dose Administration | 3/1/22- 4/17/23 |
| 0074A | Pfizer-BioNTech COVID-19 Vaccine Tris-Sucrose-Booster Administration | 5/17/22- 4/17/23 |
| 91307 | Pfizer-BioNTech COVID-19 Vaccine Tris-Sucrose | 10/29/21- 4/17/23 |
| 0081A | Pfizer-BioNTech COVID-19 Pediatric Vaccine – Tris-Sucrose Administration First Dose (6 months to 4 years) | 6/17/22- 4/17/23 |
| 0082A | Pfizer-BioNTech COVID-19 Pediatric Vaccine – Tris-Sucrose Administration Second Dose (6 months to 4 years) | 6/17/22- 4/17/23 |
| 0083A | Pfizer-BioNTech COVID-19 Pediatric Vaccine — Tris-Sucrose Administration Third Dose (6 months to 4 years) | 6/17/22- 4/17/23 |
| 91308 | Pfizer-BioNTech COVID-19 Pediatric Vaccine -Tris-Sucrose (6 months to 4 years) | 6/17/22- 4/17/23 |
| 0091A | Moderna COVID-19 Pediatric Vaccine Administration -First Dose (6 years to 11 years) | 6/17/22- 4/17/23 |
| 0092A | A Moderna COVID-19 Pediatric Vaccine Administration -Second Dose (6 years to 11 years) | |
| 0093A | Moderna COVID-19 Pediatric Vaccine Administration -Third Dose (6 years to 11 years) | |
| 0094A | Moderna COVID-19 Pediatric Vaccine Administration -Booster (6 years to 11 years) | |
| 91309 | | |
| 0104A* | Sanofi Pasteur COVID-19 Booster | TBD |
| 91310* | Sanofi Pasteur COVID-19 Vaccine | TBD |
| 0111A | Moderna COVID-19 Pediatric (6months to 5 years) - First Dose | 6/17/22- 4/17/23 |
| 0112A | Moderna COVID-19 Pediatric (6months to 5 years) - Second Dose | 6/17/22- 4/17/23 |
| 0113A | Moderna COVID-19 Pediatric (6months to 5 years) - Third Dose | 6/17/22- 4/17/23 |
| 91311 Moderna COVID-19 Pediatric (6months to 5 years) | | 6/17/22- 4/17/23 |



CHAPTER 300 – FINANCE

| | | EFFECTIVE |
|----------|--|----------------------|
| CPT CODE | DESCRIPTION | DATES |
| 0124A | 0124A Pfizer- BioNTech COVID-19 Bivalent Booster | |
| | | |
| 91312 | Pfizer- BioNTech COVID-19 Bivalent Booster | 8/31/22- |
| | | 10/31/23 |
| 0134A | Moderna COVID-19 Vaccine Bivalent Booster | 8/31/22- |
| 04242 | Made and COVID 40 Variation Bit along December | 10/31/23 |
| 91313 | Moderna COVID-19 Vaccine Bivalent Booster | 8/31/22- 10/31/23 |
| 0144A | Moderna COVID-19 Vaccine Bivalent Booster | 8/31/22- |
| 0144A | Woderna COVID-13 Vaccine bivalent booster | 10/31/23 |
| 91314 | Moderna COVID-19 Vaccine Bivalent Booster | 8/31/22- |
| | | 10/31/23 |
| 0154A | Pfizer-BioNTech COVID-19 Bivalent Booster | 8/31/22- |
| | | 10/31/23 |
| 91315 | Pfizer-BioNTech COVID-19 Bivalent Booster | 8/31/22- |
| | | 10/31/23 |
| 0164A | Moderna COVID-19, Vaccine, Bivalent | 12/8/22- |
| | | 10/31/23 |
| 91316 | Moderna COVID-19, Vaccine, Bivalent | 12/8/22- |
| 04704 | | 10/31/23 |
| 0173A | Pfizer-BioNTech COVID-19 Bivalent (6 months to 6 years), Third Dose | 12/8/22- 10/31/23 |
| 0174A | | |
| 0174A | O174A Pfizer-BioNTech COVID-19 Bivalent (6 months to 6 years), Fourth Dose | |
| 91317 | | |
| | Dose | 12/8/22- 10/31/23 |
| 0121A | Pfizer-BioNTech COVID-19 Bivalent (12 years and older) | 4/18/23- |
| | Administration Single dose | 10/31/23 |
| 0151A | Pfizer-BioNTech COVID-19 Bivalent (5-11 years and older) | 4/18/23- |
| | Administration Single dose | 10/31/23 |
| 0171A | Pfizer-BioNTech COVID-19 Bivalent (6 months -4 years and | 4/18/23- |
| | older) Administration Single dose | 10/31/23 |
| 0172A | Pfizer-BioNTech COVID-19 Bivalent (6 months -4 years and | 4/18/23- |
| 01414 | older) Administration Second dose | 10/31/23 |
| 0141A | Moderna COVID-19 Vaccine, Bivalent Pediatric Vaccine (6 months through 11 years) Administration-First Dose | 4/18/23- 10/31/23 |
| 0142A | Moderna COVID-19 Vaccine, Bivalent Pediatric Vaccine (6 | 4/18/23- |
| 01424 | months through 11 years) Administration-Second Dose | 10/31/23 |
| M0201 | COVID-19 Vaccine Home Administration | 6/8/21-TBD |
| 5201 | 55 1.2 25 15555bille / lailillinociación | 0,0,11.00 |



CHAPTER 300 – FINANCE

The following National Drug Codes (NDC) will be used for all vaccines provided in a pharmacy by a pharmacist (Provider Type 03). If the code has an asterisk (*) next to it, it is not currently approved for use.

| NDC | Description | Effective Dates |
|--------------|---|------------------|
| 00069202501 | Comirnaty 30 MCG/0.3ml | 2/24/22-6/13/26 |
| 00069202510 | Comirnaty 30 MCG/0.3ml | 2/24/22-6/13/26 |
| 00069202525 | Comirnaty 30 MCG/0.3ml | 2/24/22-6/13/26 |
| 00069236201 | Comirnaty 30 MCG/0.3ml | 9/11/23-9/11/27 |
| 00069236210 | Comirnaty 30 MCG/0.3ml | 9/11/23-9/11/27 |
| 00069239201 | Comirnaty 30 MCG/0.3ml | 9/11/23-9/4/27 |
| 00069239210 | Comirnaty 30 MCG/0.3ml | 9/11/23-9/4/27 |
| 00310122210* | Astra Zeneca COVID-19 Vaccine | 12/29/20-8/10/24 |
| 00310122215* | Astra Zeneca COVID-19 Vaccine | 12/29/20-8/10/24 |
| 59267007801 | Pfizer-BioNTech COVID-19 Vaccine | 1/27/22-4/25/26 |
| 59267007804 | Pfizer-BioNTech COVID-19 Vaccine | 1/27/22-4/25/26 |
| 59267030401 | Pfizer-BioNTech COVID-19 Bivalent | 9/1/22-9/26/26 |
| 59267030402 | Pfizer-BioNTech COVID-19 Bivalent | 9/1/22-9/26/26 |
| 59267056501 | Pfizer-BioNTech COVID-19 Bivalent | 9/1/22-9/26/26 |
| 59267056502 | Pfizer-BioNTech COVID-19 Bivalent | 9/1/22-9/26/26 |
| 59267060901 | Pfizer-BioNTech COVID-19 Bivalent 6mo-4yr | 10/27/22-9/26/26 |
| 59267060902 | Pfizer COVID-19 Bivalent 6mo-4yr | 10/27/22-9/26/26 |
| 59267100001 | Pfizer-BioNTech COVID-19 Vaccine Vial | 11/1/20-4/25/26 |
| 59267100002 | Pfizer-BioNTech COVID-19 Vaccine Carton | 11/1/20-4/25/26 |
| 59267100003 | Pfizer-BioNTech COVID-19 Vaccine Diluent | 11/1/20-4/25/26 |
| 59267102501 | Pfizer-BioNTech COVID-19-Vial | 9/29/21-4/25/26 |
| 59267102502 | Pfizer-BioNTech COVID-19 Vaccine | 9/29/21-4/25/26 |
| 59267102503 | Pfizer-BioNTech COVID-19 Vaccine | 9/29/21-4/25/26 |
| 59267102504 | Pfizer-BioNTech Vaccine | 9/29/21-4/25/26 |
| 59267105501 | Pfizer-BioNTech COVID-19 Vaccine-Vial | 9/24/21-4/25/26 |
| 59267105502 | Pfizer-BioNTech COVID-19 Vaccine | 9/24/21-4/25/26 |
| 59267105504 | Pfizer-BioNTech COVID-19 Vaccine | 9/24/21-4/25/26 |
| 59267140401 | Pfizer-BioNTech Bivalent Vaccine | 9/1/22-9/26/26 |
| 59267140402 | Pfizer COVID-19 Bivalent | 9/1/22-9/26/26 |
| 59267431501 | Pfizer COVID-19 Vac-Tris 6m-4years | 8/31/23-9/4/27 |
| 59267431502 | Pfizer COVID-19 Vac-Tris 6m-4years | 8/31/23-9/4/27 |
| 59267433101 | Pfizer COVID-19 Vac-Tris 5-11years | 8/31/23-9/11/27 |



AHCCCS CONTRACTOR OPERATIONS MANUAL CHAPTER 300 – FINANCE

| NDC | Description | Effective Dates |
|-------------|---|------------------|
| 59267433102 | Pfizer COVID-19 Vaccine Tris 5-11years | 8/31/23-9/11/27 |
| 59676058005 | Janssen COVID-19 Vaccine | 1/7/21-7/4/26 |
| 59676058015 | Janssen COVID-19 Vaccine Carton | 1/7/21-7/18/26 |
| 80631010001 | Novavax COVID-19 5 MCG/0.5ML | 4/28/21-10/10/26 |
| 80631010010 | Novavax COVID-19 5 MCG/0.5ML | 4/28/21-10/10/26 |
| 80631010201 | Novavax COVID-19 5 MCG/0.5ML | 2/23/23-10/10/26 |
| 80631010210 | Novavax COVID-19 5 MCG/0.5ML | 2/23/23-10/10/26 |
| 80631010301 | Novavax COVID-19 Vaccine 5 MCG/0.5ml | 8/31/23-10/10/26 |
| 80631010310 | Novavax COVID-19 Vaccine 5 MCG/0.5ml | 8/31/23-10/10/26 |
| 80631010501 | Novavax COVID-19 Vaccine 5 MCG/0.5ml | 8/31/23-9/4/27 |
| 80631010502 | Novavax COVID-19 Vaccine 5 MCG/0.5ml | 8/31/23-9/4/27 |
| 80777010011 | Moderna Spikevax COVID-19 Vaccine | 5/24/22-6/13/26 |
| 80777010099 | Moderna Spikevax COVID-19 Vaccine | 5/24/22-6/13/26 |
| 80777010201 | Moderna, Spikevax COVID-19 Vaccine 50 MCG/0.5 | 9/11/23-9/4/27 |
| 80777010204 | Spikevax COVID-19 Vaccine 50 MCG/0.5 | 9/11/23-9/4/27 |
| 80777010293 | Moderna, Spikevax COVID-19 Vaccine 50 MCG/0.5 | 9/11/23-9/4/27 |
| 80777010295 | Moderna, Spikevax COVID-19 Vaccine 50 MCG/0.5 | 9/11/23-9/4/27 |
| 80777010296 | Moderna, Spikevax COVID-19 Vaccine 50 MCG/0.5 | 9/11/23-9/4/27 |
| 80777027310 | Moderna COVID-19 Vaccine Vial | 10/29/20-4/25/26 |
| 80777027315 | Moderna COVID-19 Vaccine | 4/7/20-4/25/26 |
| 80777027398 | Moderna COVID-19 Vaccine | 4/7/20-4/25/26 |
| 80777027399 | Moderna COVID-19 Vaccine Carton | 10/29/20-4/25/26 |
| 80777027505 | Moderna COVID-19 Vaccine | 2/24/22-4/25/26 |
| 80777027599 | Moderna COVID-19 Vaccine Carton | 2/24/22-4/25/26 |
| 80777027705 | Moderna COVID-19 Vaccine | 4/27/22-6/28/25 |
| 80777027799 | Moderna COVID-19 Vaccine | 4/27/22-6/28/25 |
| 80777027905 | Moderna COVID-19 Vaccine | 4/27/22-4/25/26 |
| 80777027999 | Moderna COVID-19 Vaccine | 4/27/22-4/25/26 |
| 80777028005 | Moderna COVID-19 Bivalent Booster | 7/5/22-9/6/25 |
| 80777028099 | Moderna COVID-19 Bivalent Booster | 7/5/22-9/6/25 |
| 80777028205 | Moderna COVID-19 Vaccine, Bivalent | 9/1/22-9/26/26 |
| 80777028299 | Moderna COVID-19 Vaccine, Bivalent | 9/1/22-9/26/26 |
| 80777028302 | Moderna COVID-19 Vaccine, Bivalent | 10/27/22-9/26/26 |
| 80777028399 | Moderna COVID-19 Bivalent Booster | 10/27/22-9/26/26 |
| 80777028707 | Moderna, COVID-19 MRNA VACCINE 6MO-11YR- MODERNA IM SUSP 25 MCG/0.25ML | 8/31/23-9/4/27 |



CHAPTER 300 - FINANCE

| NDC | Description | Effective Dates |
|-------------|--|-----------------|
| 80777028792 | Moderna, COVID-19 MRNA VACCINE 6MO-11YR- | 8/31/23-9/4/27 |
| | MODERNA IM SUSP 25 MCG/0.25ML | |

AHCCCS RESPONSIBILITIES

1. AHCCCS Division of Business Finance (DBF) shall pull fully adjudicated and approved encounters with only the CPT and NDC codes listed above. These pulls shall be made based on the following schedule:

| | CYE 22 | CYE 23 | CYE 24 |
|------------|----------------|----------------|----------------|
| Pull #1 | March 2022 | March 2023 | February 2024 |
| Pull #2 | September 2022 | September 2023 | May 2024 |
| Final Pull | September 2023 | September 2024 | September 2025 |

The cost settlement shall be conducted and payments, including Premium Tax, shall be made after each data pull. The cost settlement shall be conducted multiple times to identify and settle any Vaccine Costs and Vaccine Administration Costs not previously settled. All COVID-19 encounters adjudicated and approved after September 2023, September 2024, and September 2025 data pull, shall not be cost settled and shall not be included in any reconciliations or other cost settlements for their respective contract years.

AHCCCS does not intend to separately cost settle COVID-19 vaccines for CYE 25 (October 1, 2024, to September 30, 2025) and later.

- 2. AHCCCS shall provide the Contractor the data supporting the cost settlement and provide written notice of the deadlines for review and comment by the Contractor. Upon completion of the review period, AHCCCS shall evaluate Contractor comments and make any adjustments to the data as warranted. AHCCCS shall then process a payment based on the total amount paid for COVID-19 vaccinations less the previous payments made, including premium tax. Refer to Attachment A for an example cost settlement.
- 3. AHCCCS shall reimburse the Contractor the lesser of the amount paid by the Contractor to the provider, or the Fee-For-Service (FFS) rates in effect at the time of the vaccine administration for the Vaccine Cost and Vaccine Administration Costs. After September 11, 2023, AHCCCS shall also reimburse the Contractor the lesser of the amount paid by the Contractor to the provider, or the Medicare ASP file rate for the cost of the vaccine. All cost settlements to the Contractor shall include premium tax.

ARIZANA HEALTH CARE COST CONTAINMENT SYSTEM

AHCCCS CONTRACTOR OPERATIONS MANUAL

CHAPTER 300 - FINANCE

B. CONTRACTOR RESPONSIBILITIES

- 1. The Contractor shall submit encounters for COVID-19 Vaccine Costs and Vaccine Administration Costs and those encounters shall reach fully adjudicated and approved status by the date required by AHCCCS. AHCCCS shall only utilize fully adjudicated and approved encounters reported by the Contractor to determine the cost settlement.
- 2. The Contractor shall maintain financial statements that separately identify COVID-19 cost settlements as required by Contract and in the format specified in the AHCCCS Financial Reporting Guide.